Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Botulinum neurotoxin Type A inhibitor
- Development stage
- Preclinical
- Lead developer
- Hawaii Biotech
- Modality
- Small Molecules
- Administration
- Intramuscular, Intradermal, Subcutaneous
01
Overview
Botulinum neurotoxin Type A inhibitor is a small-molecule therapeutic being developed by Hawaii Biotech for the treatment of botulism. The drug is designed to target the light chain (LC) of the Botulinum neurotoxin Type A (BoNT/A), which is a zinc-dependent metalloprotease. In a botulism infection, BoNT/A cleaves SNAP-25, a protein essential for the fusion of synaptic vesicles with the presynaptic membrane, thereby blocking the release of acetylcholine and causing flaccid paralysis. By inhibiting the enzymatic activity of the toxin's light chain, this small molecule aims to prevent the cleavage of SNAP-25, halting the progression of paralysis and potentially allowing for faster recovery. This program is part of Hawaii Biotech's focus on developing medical countermeasures for biodefense and infectious diseases.
- Other names
- BoNT/A inhibitorHawaii Biotech BoNT/A inhibitor
02
Targets
BoNT/A-LC (Botulinum neurotoxin type A light chain)
Beyond the preview
Go deeper on Botulinum neurotoxin Type A inhibitor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Botulinum neurotoxin Type A inhibitor.